TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial.

Yijie Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.